leuprolide acetate
leuprolide acetate is listed in the FDA National Drug Code directory with 31 NDC codes, marketed under brand names including Lupron Depot-PED, Lupron Depot, Leuprolide Acetate. Available dosage forms: kit, injection, powder, lyophilized, for suspension.
Drug details
- Generic Name
- leuprolide acetate
- Brand Names
- Lupron Depot-PED, Lupron Depot, Leuprolide Acetate, LUTRATE DEPOT, leuprolide acetate, LEUPROLIDE ACETATE DEPOT
- Application Number
- NDA020263
- Sponsor
- AbbVie Inc.
- NDC Codes
- 31
- Dosage Forms
- KIT, INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION
- Routes
- SUBCUTANEOUS
- Active Ingredients
- LEUPROLIDE ACETATE
Indications and Usage
INDICATIONS AND USAGE Leuprolide acetate injection is indicated in the palliative treatment of advanced prostatic cancer.
Warnings
WARNINGS Initially, leuprolide acetate injection, like other LH-RH agonists, causes increases in serum levels of testosterone. Transient worsening of symptoms, or the occurrence of additional signs and symptoms of prostate cancer, may develop during the first few weeks of leuprolide acetate injection treatment. Patients may experience a temporary increase in bone pain, which can be managed symptomatically. As with other LH-RH agonists, ureteral obstruction and spinal cord compression have been observed, which may contribute to paralysis with or without fatal complications. Safe use of leuprolide acetate in pregnancy has not been established clinically. Leuprolide acetate injection may cause fetal harm. Periodic monitoring of serum testosterone and prostate-specific antigen (PSA) levels is recommended, especially if the anticipated clinical or biochemical response to treatment has not been achieved. It should be noted that results of testosterone determinations are dependent on assay methodology. It is advisable to be aware of the type and precision of the assay methodology to make appropriate clinical and therapeutic decisions. Severe Cutaneous Adverse Reactions Leuprolide acetate can cause severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) and acute generalized exanthematous pustulosis (AGEP). SCARs, including SJS/TEN, DRESS, and AGEP, occurred in patients receiving leuprolide acetate; including cases with visceral involvement and/or requiring skin grafts [see Adverse Reactions]. Monitor patients for the development of SCARs. If a SCAR is suspected, interrupt leuprolide acetate until the etiology of the reaction has been determined. Consultation with a dermatologist is recommended. If a SCAR is confirmed or for other grade 4 skin reactions, permanently discontinue leuprolide acetate.